On 28 February 2020, Harbour BioMed announced FDA approval of its Investigational New Drug application for HBM4003, an anti-CTLA-4 antibody and candidate for the treatment of advanced solid tumours.
How’s Your Hamstring?
Vald Pty Ltd v KangaTech Pty Ltd (No 5) [2024] FCA 333 and Vald Pty Ltd v KangaTech Pty Ltd (No 6) [2024] FCA 408 ...